학술논문
The Ginsenoside Compound K Suppresses Stem-Cell-like Properties and Colorectal Cancer Metastasis by Targeting Hypoxia-Driven Nur77-Akt Feed-Forward Signaling
Document Type
Report
Author
Source
Cancers. December 2022, Vol. 15 Issue 1
Subject
Language
English
ISSN
2072-6694
Abstract
Author(s): Minda Zhang [1,†]; Zeyu Shi [2,†]; Shuaishuai Zhang [1]; Xudan Li [1]; Sally Kit Yan To [2]; Yijia Peng [1]; Jie Liu [1]; Siming Chen [1]; Hongyu Hu [3]; [...]
Compound K (CK) is the major functional ginsenoside metabolite derived from ginseng, one of the most popular traditional Chinese medicines, with unknown mechanistic targets. We describe here that CK directly binds and modulates Nur77 phosphorylation to deplete cancer stem-cell-like cells (CSCs) and suppress colorectal cancer (CRC) metastasis. Mechanistically, CK disrupts an unprecedented Nur77-Akt feed-forward loop to inactivate PI3K/Akt, which promotes and maintains the properties of CSCs under a hypoxic microenvironment. We thus identify Nur77 as the direct target of CK and dissect a novel mechanism for its action in CRC. Hypoxia reprograms cancer stem cells. Nur77, an orphan nuclear receptor, highly expresses and facilitates colorectal cancer (CRC) stemness and metastasis under a hypoxic microenvironment. However, safe and effective small molecules that target Nur77 for CSC depletion remain unexplored. Here, we report our identification of the ginsenoside compound K (CK) as a new ligand of Nur77. CK strongly inhibits hypoxia-induced CRC sphere formation and CSC phenotypes in a Nur77-dependent manner. Hypoxia induces an intriguing Nur77-Akt feed-forward loop, resulting in reinforced PI3K/Akt signaling that is druggable by targeting Nur77. CK directly binds and modulates Nur77 phosphorylation to block the Nur77-Akt activation loop by disassociating Nur77 from the p63-bound Dicer promoter. The transcription of Dicer that is silenced under a hypoxia microenvironment is thus reactivated by CK. Consequently, the expression and processing capability of microRNA let-7i-5p are significantly increased, which targets PIK3CA mRNA for decay. The in vivo results showed that CK suppresses cancer stemness and metastasis without causing significant adverse effects. Given that the majority of FDA-approved and currently clinically tested PI3K/Akt inhibitors are reversible ATP-competitive kinase antagonists, targeting Nur77 for PI3K/Akt inactivation may provide an alternative strategy to overcoming concerns about drug selectivity and safety. The mechanistic target identification provides a basis for exploring CK as a promising nutraceutical against CRC.
Compound K (CK) is the major functional ginsenoside metabolite derived from ginseng, one of the most popular traditional Chinese medicines, with unknown mechanistic targets. We describe here that CK directly binds and modulates Nur77 phosphorylation to deplete cancer stem-cell-like cells (CSCs) and suppress colorectal cancer (CRC) metastasis. Mechanistically, CK disrupts an unprecedented Nur77-Akt feed-forward loop to inactivate PI3K/Akt, which promotes and maintains the properties of CSCs under a hypoxic microenvironment. We thus identify Nur77 as the direct target of CK and dissect a novel mechanism for its action in CRC. Hypoxia reprograms cancer stem cells. Nur77, an orphan nuclear receptor, highly expresses and facilitates colorectal cancer (CRC) stemness and metastasis under a hypoxic microenvironment. However, safe and effective small molecules that target Nur77 for CSC depletion remain unexplored. Here, we report our identification of the ginsenoside compound K (CK) as a new ligand of Nur77. CK strongly inhibits hypoxia-induced CRC sphere formation and CSC phenotypes in a Nur77-dependent manner. Hypoxia induces an intriguing Nur77-Akt feed-forward loop, resulting in reinforced PI3K/Akt signaling that is druggable by targeting Nur77. CK directly binds and modulates Nur77 phosphorylation to block the Nur77-Akt activation loop by disassociating Nur77 from the p63-bound Dicer promoter. The transcription of Dicer that is silenced under a hypoxia microenvironment is thus reactivated by CK. Consequently, the expression and processing capability of microRNA let-7i-5p are significantly increased, which targets PIK3CA mRNA for decay. The in vivo results showed that CK suppresses cancer stemness and metastasis without causing significant adverse effects. Given that the majority of FDA-approved and currently clinically tested PI3K/Akt inhibitors are reversible ATP-competitive kinase antagonists, targeting Nur77 for PI3K/Akt inactivation may provide an alternative strategy to overcoming concerns about drug selectivity and safety. The mechanistic target identification provides a basis for exploring CK as a promising nutraceutical against CRC.